Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
A Phase II Study of AK102 in Patients With Heterozygous Familial Hypercholesterolemia
CTR20191935Phase 2Completed
- Sponsor
- Kangrong Oriental
- Start
- Nov 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of ebronucimab in heterozygous familial hypercholesterolemia (HeFH), sponsored by Kangrong Oriental. Started Nov 2019; status: completed.
02
Drugs
ebronucimab
03
Conditions
heterozygous familial hypercholesterolemia (HeFH)
Beyond the preview
Go deeper on CTR20191935.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20191935.